Drug intelligence / Profile preview

KC-11458

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

KC-11458 is a small molecule **motilin receptor agonist** developed as a prokinetic agent to accelerate gastric emptying, particularly targeting gastric motility disorders such as gastroparesis. Unlike some motilin agonists (like antibiotics such as erythromycin), KC-11458 does not have antibiotic properties[1]. In controlled clinical studies, KC-11458 failed to show significant improvement in gastric emptying in patients with diabetic gastroparesis and was associated with a slight worsening of upper GI symptoms[1].

Targets

MLNR (Human motilin receptor)

Beyond the preview

Go deeper on KC-11458.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KC-11458.

Explore the full profile